Overview

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Status:
Completed

Trial end date:
2020-06-09

Target enrollment:

Participant gender:

Summary

To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals